Literature DB >> 31452281

miR-125a suppresses malignancy of multiple myeloma by reducing the deubiquitinase USP5.

Liting Wu1, Cui Zhang1, Min Chu1, Yingchao Fan1, Lu Wei1, Zhumeng Li1, Yonghua Yao1, Wenfang Zhuang1.   

Abstract

miR-125a is a microRNA that is frequently diminished in various human malignancies. However, the mechanism by which impaired miR-125a promotes cancer growth remains undefined. In this study, we investigated the role of miR-125a in the proliferation and apoptosis of multiple myeloma (MM). To do this, we used MM tissue samples (from 40 anonymous patients), normal matched control samples, and five MM-derived cell lines. We also established a mouse model of MM xenograft to explore the effect of overexpression of miR-125a on the MM growth in vivo. Quantitative real-time polymerase chain reaction revealed that the miR-125a expression was broadly reduced in MM tissues and cell lines. The impairment of miR-125a in MM tissues was functionally relevant because the overexpression of miR-125a remarkably decreased the cell viability and colony-forming activity, at least in part, by promoting apoptosis in two miR-125a-deficient MM cell lines: NCI-H929 and U266. Interestingly, we also discovered that the human gene encoding the ubiquitin-specific peptidase 5 (USP5), which is known to promote cellular deubiquitination and ubiquitin/proteasome-dependent proteolysis, was a direct transcriptional target for miR-125a to repress. More importantly, the heterologous expression of USP5 significantly reversed the growth-inhibitory effects of miR-125a on MM cells in vitro. In the mouse xenograft model, overexpressed miR-125a prominently inhibited the growth of MM tumors and concomitantly reduced the expression of USP5 in tumor tissues. These results suggest that miR-125a inhibits the expression of USP5, thereby mitigating the proliferation and survival of malignant MM cells. We propose that USP5 acts as an oncoprotein in miR-125a-missing cancers.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  USP5; apoptosis; cell proliferation; miR-125a; multiple myeloma

Mesh:

Substances:

Year:  2019        PMID: 31452281     DOI: 10.1002/jcb.29309

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

Review 1.  Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2020 Jul-Aug       Impact factor: 4.069

2.  Ubiquitin-Specific Peptidase 5 is Involved in the Proliferation of Trophoblast Cells by Regulating Wnt/β-Catenin Signaling.

Authors:  Liu Li; Shuo Wang; Ming Wang; Guoqing Qi; Hongliang Zhao
Journal:  Mol Biotechnol       Date:  2021-05-11       Impact factor: 2.695

3.  Long non-coding RNA NEAT1 serves as a novel biomarker for treatment response and survival profiles via microRNA-125a in multiple myeloma.

Authors:  Haifeng Yu; Shuailing Peng; Xi Chen; Shuiyun Han; Jialin Luo
Journal:  J Clin Lab Anal       Date:  2020-07-01       Impact factor: 2.352

Review 4.  Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.

Authors:  Amro M Soliman; Teoh Seong Lin; Pasuk Mahakkanukrauh; Srijit Das
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

Review 5.  Deubiquitinases: Modulators of Different Types of Regulated Cell Death.

Authors:  Choong-Sil Lee; Seungyeon Kim; Gyuho Hwang; Jaewhan Song
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

6.  Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1.

Authors:  Zhiwei Zhang; Zihan Cui; Zhuolin Xie; Chang Li; Chun Xu; Xia Guo; Jie Yu; Tengfei Chen; Francesco Facchinetti; Hanibal Bohnenberger; Tracy L Leong; Yufeng Xie; Xinliang Mao; Jun Zhao
Journal:  Transl Lung Cancer Res       Date:  2021-10

7.  Glaucocalyxin A suppresses multiple myeloma progression in vitro and in vivo through inhibiting the activation of STAT3 signaling pathway.

Authors:  Mei Li; Cailong Chen; Qian Wang; Xiaolu Jiang; Lanlan Tan; Ying Huang; Yan Zhang; Zubin Zhang
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.